Cabaletta Bio (CABA)
(Delayed Data from NSDQ)
$3.95 USD
-0.07 (-1.74%)
Updated Sep 25, 2024 03:59 PM ET
After-Market: $3.96 +0.01 (0.25%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth B Momentum D VGM
Income Statements
Fiscal Year end for Cabaletta Bio, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 75 | 54 | 46 | 34 | 19 |
Income After Depreciation & Amortization | -75 | -54 | -46 | -34 | -19 |
Non-Operating Income | 7 | 1 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -68 | -53 | -46 | -33 | -17 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -68 | -53 | -46 | -33 | -17 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -68 | -53 | -46 | -33 | -17 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -74 | -53 | -46 | -33 | -19 |
Depreciation & Amortization (Cash Flow) | 1 | 2 | 1 | 0 | 0 |
Income After Depreciation & Amortization | -75 | -54 | -46 | -34 | -19 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 41.02 | 29.27 | 25.72 | 23.15 | 5.47 |
Diluted EPS Before Non-Recurring Items | -1.65 | -1.81 | -1.80 | -1.44 | -4.07 |
Diluted Net EPS (GAAP) | -1.65 | -1.81 | -1.80 | -1.44 | -4.07 |
Fiscal Year end for Cabaletta Bio, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 30.28 | 28.03 | 23.15 | 18.67 | 15.89 |
Income After SG&A, R&D, and Dept/Amort Expenses | -30.28 | -28.03 | -23.15 | -18.67 | -15.89 |
Non-Operating Income | 2.68 | 2.98 | 2.26 | 2.22 | 1.40 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | -27.60 | -25.05 | -20.89 | -16.45 | -14.49 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -27.60 | -25.05 | -20.89 | -16.45 | -14.49 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -27.60 | -25.05 | -20.89 | -16.45 | -14.49 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 49.29 | 49.11 | 45.40 | 44.45 | 39.15 |
Diluted EPS Before Non-Recurring Items | -0.56 | -0.51 | -0.46 | -0.37 | -0.37 |
Diluted Net EPS (GAAP) | -0.56 | -0.51 | -0.47 | -0.36 | -0.37 |